Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths
- PMID: 16230904
- DOI: 10.1097/01.rli.0000184756.66360.d3
Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths
Abstract
Rationale and objectives: To characterize and compare commercially available contrast media (CM) for magnetic resonance imaging (MRI) in terms of their relaxivity at magnetic field strengths ranging from 0.47 T to 4.7 T at physiological temperatures in water and in plasma. Relaxivities also were quantified in whole blood at 1.5 T.
Methods: Relaxivities of MRI-CM were determined by nuclear magnetic resonance (NMR) spectroscopy at 0.47 T and MRI phantom measurements at 1.5 T, 3 T, and 4.7 T, respectively. Both longitudinal (T1) and transverse relaxation times (T2) were measured by appropriate spin-echo sequences. Nuclear magnetic resonance dispersion (NMRD) profiles were also determined for all agents in water and in plasma.
Results: Significant dependencies of relaxivities on the field strength and solvents were quantified. Protein binding leads to both increased field strength and solvent dependencies and hence to significantly altered T1 relaxivity values at higher magnetic field strengths.
Conclusions: Awareness of the field strength and solvent associated with relaxivity data is crucial for the comparison and evaluation of relaxivity values. Data observed at 0.47 T can thus be misleading and should be replaced by relaxivities measured at 1.5 T and at 3 T in plasma at physiological temperature.
Similar articles
-
Water-soluble gadofullerenes: toward high-relaxivity, pH-responsive MRI contrast agents.J Am Chem Soc. 2005 Jan 19;127(2):799-805. doi: 10.1021/ja044688h. J Am Chem Soc. 2005. PMID: 15643906
-
T1 relaxivities of gadolinium-based magnetic resonance contrast agents in human whole blood at 1.5, 3, and 7 T.Invest Radiol. 2015 May;50(5):330-8. doi: 10.1097/RLI.0000000000000132. Invest Radiol. 2015. PMID: 25658049
-
Macrocyclic Gd3+ chelates attached to a silsesquioxane core as potential magnetic resonance imaging contrast agents: synthesis, physicochemical characterization, and stability studies.Inorg Chem. 2010 Jul 5;49(13):6124-38. doi: 10.1021/ic1007395. Inorg Chem. 2010. PMID: 20527901
-
Optimization of gadolinium-based MRI contrast agents for high magnetic-field applications.Future Med Chem. 2010 Mar;2(3):385-96. doi: 10.4155/fmc.09.174. Future Med Chem. 2010. PMID: 21426173 Review.
-
Surface impact on nanoparticle-based magnetic resonance imaging contrast agents.Theranostics. 2018 Apr 3;8(9):2521-2548. doi: 10.7150/thno.23789. eCollection 2018. Theranostics. 2018. PMID: 29721097 Free PMC article. Review.
Cited by
-
Biocytin-derived MRI contrast agent for longitudinal brain connectivity studies.ACS Chem Neurosci. 2011 Oct 19;2(10):578-87. doi: 10.1021/cn200022m. Epub 2011 Aug 3. ACS Chem Neurosci. 2011. PMID: 22860157 Free PMC article.
-
A Gadolinium(III) Complex Based on the Thymine Nucleobase with Properties Suitable for Magnetic Resonance Imaging.Int J Mol Sci. 2021 Apr 27;22(9):4586. doi: 10.3390/ijms22094586. Int J Mol Sci. 2021. PMID: 33925589 Free PMC article.
-
Studying the effect of particle size and coating type on the blood kinetics of superparamagnetic iron oxide nanoparticles.Int J Nanomedicine. 2012;7:4447-58. doi: 10.2147/IJN.S33120. Epub 2012 Aug 10. Int J Nanomedicine. 2012. PMID: 22927759 Free PMC article.
-
Large T1 contrast enhancement using superparamagnetic nanoparticles in ultra-low field MRI.Sci Rep. 2018 Aug 8;8(1):11863. doi: 10.1038/s41598-018-30264-5. Sci Rep. 2018. PMID: 30089881 Free PMC article.
-
Safety of gadobutrol: results of a non-interventional study of 3710 patients, including 404 children.Acta Radiol. 2019 Jul;60(7):873-879. doi: 10.1177/0284185118801151. Epub 2018 Sep 25. Acta Radiol. 2019. PMID: 30253660 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical